Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly Requests Emergency Use Authorization for COVID-19 Treatment Candidate

By Cory Renauer – Oct 7, 2020 at 1:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

New clinical trial data strongly suggests treatment with its antibody therapies makes a big difference for COVID-19 positive patients.

Eli Lilly (LLY 1.92%) made some important disclosures on Wednesday morning regarding a pair of coronavirus treatment candidates and their potential path to accessibility in a hospital near you. In a nutshell, new clinical trial data for LY-CoV555 and LY-CoV016 suggest the pair of antibodies go a long way toward improving outcomes for COVID-19 patients.

Scientist in a laboratory.

Image source: Getty Images.

More from LY-CoV555 and LY-CoV016 to come

Based on a recent interim analysis, the company has submitted an initial request to the FDA for an emergency use authorization (EUA) that would allow physicians to administer LY-CoV555 to higher-risk patients diagnosed with mild-to-moderate COVID-19. The amount of SARS-CoV-2 circulating in the bloodstreams of patients treated with LY-CoV555 as a monotherapy fell significantly compared to those given a placebo, and it looks like combining LY-CoV555 with LY-CoV016 is even more effective.

Since the initiation of the study, we've learned that by day 11, most patients have already cleared the virus completely from their systems with standard care. This extra challenge didn't prevent the combination of LY-CoV555 and LY-CoV016 from meeting the trial's primary endpoint, which was viral load reduction 11 days after beginning treatment.

Measured by actual outcomes, it's clear that Lilly's antibody combination provides a meaningful benefit. Patients given the combo-treatment were 84.5% less likely to go to the hospital for COVID-19-related reasons than those randomized to receive a placebo.

Eli Lilly thinks it can supply 100,000 doses of LY-CoV555 monotherapy by the end of the month and have up to 1 million doses ready by the end of the year. Manufacturing of the combination treatment is much further behind, with 50,000 doses expected by the end of 2020.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$327.73 (1.92%) $6.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.